+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Advanced glycation end-products and the progress of diabetic vascular complications



Advanced glycation end-products and the progress of diabetic vascular complications



Physiological Research 53(2): 131-142



Epidemiological Studies have confirmed that hyperglycemia is the most important factor in the onset and progress of vascular complications, both in Type 1 and 2 diabetes mellitus. The formation of advanced glycation end-products (AGEs) correlates with glycemic control. The AGE hypothesis proposes that accelerated chemical modification of proteins by glucose during hyperglycemia contributes to the pathogenesis of diabetic complications including nephropathy, retinopathy, neuropathy and atherosclerosis. Recent studies have shown that increased formation of serum AGEs exists in diabetic children and adolescents with or without vascular complications. Furthermore, the presence of diabetic complications in children correlates with elevated serum AGEs. The level of serum AGEs could be considered as a marker of later developments of vascular complications in children with Type 1 and 2 diabetes mellitus. The careful metabolic monitoring of young diabetics together with monitoring of serum AGEs can provide useful information about impending AGE-related diabetic complications. It is becoming clear that anti-AGE strategies may play an important role in the treatment of young and older diabetic patients. Several potential drug candidates Such as AGE inhibitors have been reported recently.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 011733391

Download citation: RISBibTeXText

PMID: 15046548


Related references

Recent progress in advanced glycation end products and diabetic complications. Diabetes 46 Suppl 2: S19-S25, 1997

Advanced Glycation End Products (Ages) and Diabetic Vascular Complications. Current Diabetes Reviews 1(1): 93-106, 2005

The Role of Advanced Glycation End Products in Diabetic Vascular Complications. Diabetes and Metabolism Journal 42(3): 188-195, 2018

Advanced glycation end products (AGEs) and diabetic vascular complications. Current Diabetes Reviews 1(1): 93-106, 2008

Receptor for advanced glycation end-products-mediated inflammation and diabetic vascular complications. Journal of Diabetes Investigation 2(3): 155-157, 2011

The role of advanced glycation end-products (AGEs) in the development of vascular diabetic complications. Arquivos Brasileiros de Endocrinologia E Metabologia 52(6): 940-950, 2008

Controlling the receptor for advanced glycation end-products to conquer diabetic vascular complications. Journal of Diabetes Investigation 3(2): 107-114, 2012

Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications. Therapeutic Apheresis and Dialysis 13(6): 534-539, 2010

Association between Fluorescent Advanced Glycation End-Products and Vascular Complications in Type 2 Diabetic Patients. Biomed Research International 2017: 7989180, 2018

Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors. Diabetes 45 Suppl 3: S65-S66, 1996

Food-advanced glycation end products aggravate the diabetic vascular complications via modulating the AGEs/RAGE pathway. Chinese Journal of Natural Medicines 14(11): 844-855, 2017

A study on serum advanced glycation end products and its association with oxidative stress and paraoxonase activity in type 2 diabetic patients with vascular complications. Clinical Biochemistry 46(1-2): 109-114, 2013

Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications. Cardiovascular Diabetology 14: 2, 2016

Hepatocyte growth factor has a role in the amelioration of diabetic vascular complications via autophagic clearance of advanced glycation end products: Dispo85E, an HGF inducer, as a potential botanical drug. Metabolism: Clinical and Experimental 60(6): 888-892, 2011

Advanced glycation end-products in senile diabetic and non-diabetic patients with cardiovascular complications. Age 30(4): 303-309, 2009